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Abstract 
Once thought of as inert remnants of cellular processes, the significance of 
membrane vesicles is now expanding as their capacity to package and transfer 
bioactive molecules during intercellular communication is established. This ability to 
serve as vectors in the trafficking of cellular cargo is of mounting interest in the 
context of cancer, particularly in the dissemination of deleterious cancer traits from 
donor cells to recipient cells. Although microparticles (MPs) contribute to the 
pathogenesis of cancer, their unique characteristics can also be exploited in the 
context of cancer management. The detection of MPs in body fluids has the potential 
to provide an effective means for the diagnosis, prognosis and surveillance of cancer 
patients. The use of these readily accessible systemic biomarkers has the potential 
to circumvent the need for invasive biopsy procedures. In addition, the autologous 
nature of MPs may allow them to be used as novel drug delivery carriers. 
Consequently, the modulation of MP vesiculation to treat disease, the detection of 
MPs in disease monitoring, and the application of MPs as therapeutic delivery 
vehicles present prospective clinical interventions in the treatment of cancer.  
 
Keywords: Biomarker; cancer; drug delivery; metastasis; microparticle inhibitors; 
microparticles; multidrug resistance; P-glycoprotein.  
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1. Introduction  
Microparticles (MPs) are part of a general classification of extracellular vesicles 
termed microvesicles (MVs), which includes a population of membrane vesicles that 
are heterogeneous in shape, ranging in size from 0.1-1 μm and isolated from 
biological fluids or conditioned culture media [1]. Other extracellular vesicles include 
apoptotic bodies and exosomes, which differ on the basis of their size and origin. The 
irregularly shaped apoptotic bodies are released from cells undergoing apoptosis and 
fragmentation and range from 1-5 μm in size, whereas, exosomes (30-100 nm) are 
released by the fusion of multivesicular bodies with the cell membrane [1]. MPs, 
which are the focus of this review, are released from the surface of cells by the 
process of outward membrane budding through a loss of calcium-dependent 
membrane phospholipid asymmetry and cytoskeletal rearrangement [2]. MPs are 
therefore composed of fragments of the parent cell, which comprise the plasma 
membrane proteins and cytoplasmic and nucleic constituents of the parent cell. Once 
MPs bud from the parent cell, they are released into the systemic circulation, where 
they can effectively deliver their cargo long-range to recipient cells. In this way, MPs 
serve as systemic vehicles in mediating intercellular communication. MPs have been 
found to carry various bioactive molecules, proteins and nucleic acids including 
mRNA and microRNA (miRNA) [3-6]. Thus they are involved in multiple aspects of 
cancer progression including the development of drug resistance [5, 7-10] and 
metastases [11-13], tumor angiogenesis (by the dissemination of components such 
as sphingomyelin and VEGF) [14, 15] cellular survival (by the removal of cytosolic 
caspase 3) [16, 17] and evasion of immune surveillance via the expression of 
components such as latent membrane protein (LMP-1) [18] and Fas ligand [19, 20] 
(Figure 1). In this review, we will be focusing on recent developments in the role of 
MPs in cancer and how they can be utilized clinically in cancer management.  
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2. Microparticles provide a link between drug resistance and metastasis 
MPs have been shown to confer and transfer multidrug resistance (MDR) in cancer 
cells [5, 7, 10, 21]. This we showed was mediated through the intercellular transfer of 
functional resistance proteins, such as P-glycoprotein (P-gp) and Multidrug 
resistance protein 1 (MRP-1) Figure 2 is a confocal image which shows the transfer 
of P-gp-EGFP fusion protein transferred via MPs to recipient drug sensitive cancer 
cells. We observe significant co-localization with the membrane intercalating dye 
PKH-26 following a 4 hour co-culture period. This is consistent with our previous 
reports showing functionality of transferred resistance proteins contributing to the 
acquisition of MDR in recipient cells [5, 7, 10]. The MP-mediated acquisition of MDR 
was also shown to be associated with the promotion of an enhanced metastatic 
capacity in recipient breast cancer cells [11]. The elucidation of this relationship is 
significant, as these two deleterious traits were previously considered independent. 
Although an association between the emergence of the two phenotypes had been 
alluded to previously [22-24], a definitive link and the mechanism behind this 
remained unknown. Our laboratory was the first to show that MPs serve as a conduit 
in mediating this relationship [11].  
Recipient breast cancer cells, which were both lowly metastatic and responsive to 
drug treatment, acquired an enhanced metastatic capacity with the ability to resist 
drug treatment upon co-culture with MPs derived from highly metastatic, drug-
resistant donor cells [11]. MPs derived from breast cancer MDR cells were shown to 
mediate migration, invasion and drug resistance in recipient breast cancer cells to 
yield a population that was metastatic and drug resistant (Figure 3).  
The clinical relevance of MPs as the link between metastasis and drug resistance is 
that progression of either metastatic capacity or resistance may be indicative of 
progression of the other trait also. From a therapeutic perspective this provides 
opportunities for the prevention of these deleterious cancer phenotypes. 
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3. Microparticles mediate the enhancement of metastatic traits 
Metastasis is an especially unfavorable aspect of cancer progression, whereby a 
localized population of cancer cells spreads through the lymphatic system or 
bloodstream to other parts of the body. MPs have been shown to play a role in the 
induction of an enhanced metastatic capacity in cancer in a variety of ways. MPs 
have been found to transfer matrix metalloproteinase’s (MMPs), which are capable of 
degrading the extracellular matrix, allowing metastasis and invasion by cancer cells. 
MMP-2 and MMP-9 were found in MPs released from ovarian cancer cells and breast 
cancer cells and enhanced the metastatic capacity of recipient cells [12, 25, 26]. As 
mentioned above, we also showed that MPs formed are a conduit between drug 
resistance and metastasis. This appears to be mediated via the regulation of miR-
503 and proline-rich tyrosine kinase 2 (PYK2) to promote the migration and invasive 
capacity of recipient breast cancer cells [11].  
Specifically, we confirmed that miR-503 is required for the inhibition of migration and 
invasion in breast cancer as demonstrated by wound healing migration assays and 
Matrigel®-coated transwell invasion assays [11]. This finding supported previous 
observations of reduced migration and invasion following transfection of miR-503 in 
hepatocellular carcinoma cells [27], acute myeloid leukemia cells [28], chronic 
myelogenous leukemia cells [29], osteosarcoma cells, colon cancer cells [30], head 
and neck carcinoma cells [31] and in endometrioid endometrial cancer cells [32]. 
Moreover, we showed for the first time that MPs were involved in mediating the 
effects of miR-503 in breast cancer cells. One such mechanism for the down 
regulation of miR-503 by MPs was proposed to be via the activation of the NF-κB 
signaling pathway, as NF-κB has been shown to suppress the expression of miR-503 
in epithelial cells [33]. Moreover, NF-κB has been associated with the promotion of 
migration and invasion in breast cancer [34].  
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Furthermore, PYK2 protein and mRNA was found to be upregulated in recipient cells 
following co-culture with MPs [11]. PYK2, a member of the focal adhesion kinase 
subfamily of cytoplasmic tyrosine kinases, was correlated with an increased 
metastatic capacity in a breast cancer cell line [35], a squamous cell carcinoma of the 
head and neck [36], hepatocellular carcinoma [37, 38] and prostate cancer [39]. Both 
PYK2 and miR-503 may promote metastasis in recipient cells via regulation of the 
PI3K/AKT signaling pathway. The overexpression of PYK2 was associated with 
activation of the PI3K/AKT pathway and poor survival and metastasis in 
hepatocellular carcinoma [37]. Additionally, as miR-503 targets and inhibits PI3K/AKT 
activation [40, 41], the suppression of miR-503 in recipient cells may result in the up 
regulation of PI3K/AKT signaling and the subsequent promotion of metastasis.  
Although up regulated in recipient cells, PYK2 was not found in the cargo of the MPs 
themselves [11]. This was the first demonstration that it was the dissemination of 
intermediary mediators that led to the MP-mediated regulation of PYK2 in recipient 
cells rather than the direct transfer of components packaged within the MP cargo. 
Therefore, the scope of MP involvement in the promotion of migration and invasion is 
continuously broadening.  
4. Clinical applications of microparticles and other extracellular vesicles in 
cancer 
Modulation of MP release in the management of cancer 
The subject of MP inhibitors is an emerging focus in the field. Calcium channel 
blockers [42], ROCK inhibitors [43] and pantethine [44] have been shown to prevent 
the production and release of MPs in various cell types. This new class of 
compounds has potential to provide a novel strategy in circumventing MP-mediated 
dissemination of deleterious traits and preventing cancer progression [45, 46]. In a 
recent study, we elucidated the effects of Calpain inhibitor II, vitamin B5 derivatives 
and the calcium channel blocker Verapamil hydrochloride on modulating MP-
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biosynthetic pathways. Interestingly, Calpain inhibitor II (ALLM) showed a significant 
inhibition of MP production in both resting as well as cells activated with a calcium 
ionophore, A23187, while a ROCK inhibitor (Y-27632) inhibited MP synthesis in 
activated cells only. Thereby, these novel molecules may serve as potential 
candidates in strategies employed for the prevention of MP-mediated disease 
progression in cancer [46]. 
MPs as novel drug delivery systems 
In addition to their role as indicators of disease, the capacity of MPs to carry a 
multitude of components as part of their cargo can also be exploited in drug delivery. 
Since MPs naturally function as vehicles for the delivery of bioactive molecules, the 
refinement and modification of these processes may allow MPs to be used as novel 
therapeutic vehicles in the treatment of cancer.  
MPs have been found to sequester chemotherapeutic drugs [9]. In doing so, they 
provided another means by which MPs facilitated cancer MDR. MPs do this by both 
passive and active mechanisms. Passive sequestration occurs via diffusion of 
clinically relevant chemotherapeutic drugs such as the anthracyclines daunorubicin 
and doxorubicin across the MP membrane followed by incorporation within the 
intravesicular cargo of nucleic acids and phospholipids [9]. Once trapped, the drugs 
are no longer freely available to the target site and thus cancer cells evaded therapy. 
Active sequestration occurs in MPs derived from drug-resistant cancer cells that 
carry the drug efflux transporter P-gp on their surface. A number of this P-gp is 
inside-out in orientation such that rather than its traditional function of effluxing drugs, 
this results in the actively influx of drugs into MPs where they become trapped.  
Such a mechanism for drug trapping may be harnessed for therapeutic use in a 
similar manner to that employed by synthetic liposomes [47-50]. Indeed, a study 
conducted by Tang and colleagues in 2012 [51] showed that malignant cells 
incubated with chemotherapeutics drugs were able to package these drugs in the 
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MPs released from them. These drug-loaded MPs in turn were shown to have an 
anti-tumor effect in murine tumor models without the typical side effects [51].  
The development of MPs as a viable mechanism for the delivery of therapeutic 
molecules would be advantageous over artificial vesicles as they can be isolated 
from the patient, loaded with the desired drug(s) and reintroduced into the patient 
during treatment. Therefore, complications associated with rejection and 
immunogenicity would be avoided through the use of these autologous and 
biocompatible vehicles. The potential for using such vehicles for therapeutic delivery 
has been described for exosomes [52]. The clinical viability of dendritic cell-derived 
exosomes was assessed in Phase I trials with melanoma patients [53] and in patients 
with non-small cell lung carcinoma [54], with results showing that the therapy was 
well tolerated and could produce the required therapeutic effects. In particular, there 
is mounting interest in the delivery of nucleic acids for cancer therapy using this 
same approach.  
Loaded exosomes were used to deliver exogenous short interfering RNA to the brain 
tissue of mice, resulting in specific gene knockdown of BACE1, a therapeutic target 
in Alzheimer’s disease, and reduction in β-amyloid 1-42 levels, a component of the 
amyloid plaques associated with Alzheimer’s disease [55]. Furthermore, 
microvesicles harboring suicide gene mRNA and protein from donor cells reduced 
the growth of schwannoma tumors in an orthotopic mouse model [56]. MPs have also 
been shown to selectively package miRNAs and deliver them to recipient cells to 
regulate target gene expression and cellular function [6, 57, 58]. Therefore, there is 
extensive potential to use endogenously or exogenously loaded MPs in gene therapy 
as part of cancer therapy. 
Role of MPs as biomarkers of cancer 
In addition to the applications described above, there is emerging evidence for the 
role of extracellular vesicles in disease monitoring and diagnosis by serving as 
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biomarkers in cancer. MPs have been shown to have an incredible capacity to 
incorporate constituents from the parent cell and deliver them to recipient cells, 
contributing to cancer progression and resistance [5-7, 21]. It is this very capacity 
that makes MPs a promising biomarker for the diagnosis, prognosis and surveillance 
of cancer. Circulating MPs have been detected in the blood, urine and ascites of 
cancer patients [26, 59-62]. Furthermore, elevated levels of circulating MPs have 
been detected in patients with non-small cell lung carcinoma [63] and newly 
diagnosed glioblastoma patients [64] compared to healthy controls. Additionally, 
breast cancer patients have higher levels of MPs than healthy controls or patients 
with benign breast tumors [65-67]. This supports their potential as relevant diagnostic 
markers of malignancy. 
The detection of MPs has been associated with the prognosis and clinical status of 
cancer patients. An example is provided in pancreatic cancer. Tissue factor is an 
initiator of the blood coagulation cascade and has been detected in MPs extracted 
from the plasma of patients. Increased levels of tissue factor expressing MPs were 
found to be indicative of the presence of an aggressive, metastatic and poorly 
differentiated malignant pancreatic state that could easily infiltrate peripancreatic 
vessels in patients [68]. Consistent with this was the strong association with 
thrombosis and increased mortality in patients with pancreaticobiliary cancers [69]. 
This study amongst many others lends support to the diagnostic and prognostic 
potential MPs have in cancer management. 
Due to their presence in easily extracted body fluids and their capacity to reflect the 
characteristics of the parent cell, the proteomic and nucleic profile of MPs also has 
potential to be employed in diagnosis and prognosis. This may potential circumvent 
the need in the future for invasive biopsy procedures in staging and grading of 
cancers. The determination of the molecular status of tumors allows for detection of 
specific disease markers, surveillance of cancer progression and supports 
 10 
approaches used in individualized and targeted therapies. This has potential for fast 
and efficient implementation of tailored interventions, resulting in improved clinical 
outcomes for the patient.  
Clinical applications of other membrane vesicles in cancer 
The immunotherapeutic effect of ascites derived exosomes in combination with GM-
CSF has been assessed in Phase 1 trials for the treatment of colorectal cancer. In 
this study, exosomes could induce an antigen-specific anticancer cytotoxic T 
lymphocyte response in patients, with minimal toxicity and tolerated administration 
[70]. Furthermore, an ongoing Phase II trial which assesses the efficacy of dendritic 
cell derived exosomes as autologous therapeutic vaccines in advanced non-small 
cell lung carcinoma (NSCLC) patients to stimulate their natural defences to prevent 
tumor progression [71]. The preclinical [72] and clinical data [72] are promising 
showing that dendritic cell derived exosomes serve as maintenance immunotherapy 
in patients bearing inoperable NSCLS by T-cell priming and restoring T- and NK-cell 
functions in end stage patients. Likewise, mesenchymal stem cells (MSC) derived 
MPs were shown to induce cell cycle arrest and apoptosis of different tumor cells as 
well as inhibit in vivo tumor growth [73]. This approach is potentially beneficial as MP 
inhibition of disease progression occurs in the absence of MSC differentiation into 
stromal fibroblasts which would otherwise be conducive to tumor growth [74, 75]. 
Given their small size, lack of toxicity, target specificity and tolerance in host cells, 
membrane vesicles may serve as therapeutic agents for the treatment of cancer as 
well as clinical biomarkers for disease diagnosis and monitoring based on their 
cancer specific protein, nucleic acid and lipid cargo. Clinical applications of 
membrane vesicles are still in the developmental stage and their full potential waits to 
be explored.  
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5. Conclusion 
Elucidation of the pathological role of MPs in cancer is ongoing. Understanding this 
role is critical in the development of interventions to prevent the progression of 
cancer, as well as in harnessing this natural mechanism and using it in clinical 
practice. In this way, there are three avenues by which MPs are being studied for 
improved clinical outcomes. Firstly, through the formulation of MP inhibitors as a 
novel therapeutic class in the treatment of numerous conditions arising from MP 
release and the MP-mediated intercellular communication. Secondly, harnessing 
MPs as natural vehicles in drug delivery. Utilizing circulating MPs as cancer 
biomarkers providing an effective and non-invasive form of cancer diagnosis, 
prognosis and surveillance to tailor and personalize therapy. These strategies 
highlight MPs as attractive therapeutic candidates in disease state management.  
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8. Figure Legends 
Figure 1: The role of MPs in cancer progression. MPs facilitate (A) the 
development of drug resistance through the transfer of functional drug resistance 
proteins such as P-gp and MRP-1, (B) the enhancement of metastatic potential 
enabled by the acquisition of proteases, miRNAs and protein tyrosine kinases (C) 
promotion of angiogenesis by the dissemination of components such as 
sphingomyelin and VEGF, and (D) cellular survival and evasion of immune 
surveillance via the expression of components such as caspase 3, latent membrane 
protein (LMP-1) and Fas ligand.  
Figure 2: MPs transfer P-gp to drug sensitive cells. 100 μg of MPs derived from 
human breast adenocarcinoma cells (MCF-7) transfected with EGFP tagged P-gp, 
transfer P-gp to drug sensitive MCF-7 cells following a 4 hour co-culture period. Cells 
were fixed, labeled with PKH-26 membrane dye and the cell nuclei with DAPI as per 
the manufacturer’s protocol (Sigma Aldrich, Australia). Panel A shows the merged 
channels captured, Panel B shows P-gp-EGFP in the 488 nm channel, Panel C 
shows PKH-26 in the 561 nm channel. Images were acquired on a Nikon A1 laser 
scanning confocal microscope at 100x magnification. Imaris 8 software (Bitplane AG) 
was used for 3D reconstruction of the images. Scale bar as indicated. Data are 
representative of a typical experiment. 
 
Figure 3: MPs link the development of drug resistance to an enhanced 
metastatic capacity in cancer. (A) MPs shed from highly metastatic, drug-resistant 
donor cells transfer components such as P-gp protein, mRNA and associated 
miRNAs, PYK2 and miR-503 to up regulate P-gp expression and metastatic capacity 
in lowly metastatic, drug-sensitive recipient cells. (B) Recipient cells acquire both 
drug resistant and metastatic traits to promote the evasion of chemotherapy and 
metastatic spread of cancer.  
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